Washington, D.C. 20231

Express Mail No.: EL 452 480 895 US

HE UNITED STATES PATENT AND TRADEMARK OFFICE

From application:	Examiner Winkler, U.	סד של סד	_	
• •		Ė	\equiv	■.
	Art Unit 1648	S.C.C	3	= 0
			7	_ 8
Assistant Commission	in o	`≣	_	
Box PATENT APPI	Jon	` ≣	₽°	

Sir:

This is a request for filing a ⊠ continuation □ divisional application under 37 CFR § 1.53(b), of pending prior application no. 09/676,223 filed on September 29, 2000.

of Jürgen Kleinschmidt, Dirk Grimm, Karola Rittner

PATENT APPLICATION FEE VALUE

V 1	(inventor(s) currently of record in prior application)						
	AAV-DNA COMPRISING HELPER VIRUS SEQUENCES (title of invention) 1. The filing fee is calculated below: PATENT APPLICATION FEE VALUE						
• =====================================	ТҮРЕ	NO. FILED	LESS	EXTRA	EXTRA RATE	FE	
5	Total Claims	20	-20	0	\$18.00 each	\$	0.00
	Independent	3	-3	0	\$80.00 each	\$	0.00
<u>ļ.</u>	Basic Fee					\$	710.00
Multiple Dependency Fee If Applicable (\$270.00)					\$	270.00	
				Total		\$	980.00
	50% Reduction for Independent Inventor, Nonprofit Organization or Small Business Concern					- \$	0.00
				Total Filing F	⁷ ee	\$	980.00

- \boxtimes 2. Please charge the required fee to Pennie & Edmonds LLP Deposit Account No. 16-1150. A copy of this sheet is enclosed.
- \boxtimes 3. Amend the specification by inserting before the first line the following sentence: This is a continuation of application no. 09/676,223, filed September 29, 2000.
- 4a. New formal drawings are enclosed.

4b.	⊠	Informal drawings are enclo	sed.			
5a.	×	Priority of application no. 19 Germany is claimed under 3	96 44 500.0 filed on October 25, 55 U.S.C. §119.	1996 in		
5b.	×	The certified copy has been filed April 23, 1999.	filed in prior application no. 09/2	297,225,		
6.	Ø	The prior application is assigned Transgene S.A.	gned of record to Krebsforschung	gszentrum		
7a.	⊠	A copy of the Power of Atto 09/676,223, filed September	orney filed in the prior application 29, 2000 is enclosed.	n no.		
7b.		A Power of Attorney is encl	osed.			
8.		required to be disclosed in a 1.825. It is requested that the form from prior application application as provided for be disclosed therein are the same	scleic acid and/or amino acid sequence Listing under 37 CFR ne Sequence Listing in computer no., filed on be made a part of the by 37 C.F.R. §1.821(e). The sequence as the sequences disclosed in the paper Sequence Listing from applications.	§§1.821- readable ne present uences this		
9.		enclosed paper Sequence Lis	er 37 C.F.R. §1.821(f), that the costing from application no. is the dable form submitted in application	same as the		
10.	 Additional enclosures or instructions. Enclosed is a copy of the Substitute Specification as filed in Application No. 09/676,223, filed September 29, 2000; and the Declaration and Power of Attorney as filed in the prior application; Information Disclosure Statement, PTO Form 1449 without references; and An extension of time for a period of 3 months has been filed in application serial number 09/676,223 filed September 29, 2000 for which this Continuation application claims priority. 					
Date	<u>Augu</u>	st 3, 2001 1	Respectfully submitted, Nathan A. Machin For Laura A. Coruzzi (Reg. No. PENNIE & EDMONDS LLP	47,763 (Reg. No.) 30,742)		

(212) 790-9090

1155 Avenue of the Americas New York, N.Y. 10036-2711